TMO vs AMGN: Thermo Fisher Scientific Inc. vs Amgen Inc.
Side-by-side snapshot of two Healthcare companies — key metrics from our latest data. Reference only, not investment advice.
| Metric | TMO | AMGN |
|---|---|---|
| Company | Thermo Fisher Scientific Inc. | Amgen Inc. |
| Price | $532.48 | $366.29 |
| Market Cap | $197.88B | $197.69B |
| P/E Ratio | 29.24 | 25.51 |
| EPS | $18.21 | $14.36 |
| Dividend Yield | 35.00% | 2.75% |
| 52-Week High | $643.99 | $391.29 |
| 52-Week Low | $403.36 | $269.77 |
| Industry | Diagnostics & Research | Drug Manufacturers - General |
| Exchange | NYQ | NMS |
| Employees | 125,000 | 31,500 |
Thermo Fisher Scientific Inc. and Amgen Inc. both operate in the Healthcare sector. TMO trades at a market cap of $197.88B against AMGN's $197.69B. Valuation-wise, TMO carries a trailing P/E of 29.24 versus 25.51 for AMGN. How these figures compare depends on each company's growth profile, margins and outlook — the snapshot above is a starting point for further research, not a recommendation.
Figures are from our latest data snapshot and may not reflect current market prices. See the full profiles: Thermo Fisher Scientific Inc. and Amgen Inc.. This is not financial advice.
Recommended Reading & Tools
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Philip Fisher's growth-investing classic on evaluating management and moats.
Check Price →Keep budgets, portfolios and goals in one place with a dedicated finance planner.
Check Price →Morgan Housel's short lessons on behaviour, luck and long-term wealth.
Check Price →Data snapshot: 18 July 2026 (Yahoo Finance) · Page last built: